AIH-PBC overlapping syndrome is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are critical to improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of domestic and foreign authorities with accurate diagnosis and treatment programs. Treatment and management of AIH-PBC overlapping syndrome requires individual development of treatment programs, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and other multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of AIH-PBC overlapping syndrome. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.